Novo Nordisk's latest trial results for its next generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent form of weight loss HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine